Pfizer sees positive results for Xeljanz in psoriasis; U.K.'s NICE greenlights two cancer drugs;

@FiercePharma: Google exec figures pharma could go viral on YouTube--if it tried. More from FiercePharmaMarketing. | Follow @FiercePharma

@TracyStaton: $16B deal for GlaxoSmithKline oncology meds turns Novartis into cancer heavyweight. Story | Follow @TracyStaton

@EricPFierce: Gilead turns in eye-popping results because of huge sales of Sovaldi, $2.3B in Q1 sales for the hep C drug. News | Follow @EricPFierce

@CarlyHFierce: Big Pharma sees danger, not safety, in U.S. FDA's new social media guidance. Article | Follow @CarlyHFierce

> Gilead Sciences ($GILD) beat Q1 expectations, due in large part to its brand new hep C drug Sovaldi. Story

> Pfizer ($PFE) says two Phase III studies for Xeljanz as a treatment for psoriasis showed positive results. More (sub. req.)

> Three of Valeant's ($VRX) board members won't seek reelection at the company's annual meeting next month. Story (sub. req.)

> The U.K.'s cost watchdog has given a final thumbs-up to Boehringer Ingelheim's Giotrif and Johnson & Johnson's ($JNJ) Velcade. Story

> India's Wockhardt says a regulator in northern Indian state Himachal Pradesh has suspended the manufacture and sale of one of its products. More

> GlaxoSmithKline Asia has cut the price on fever and pain-relief pill Crocin Advance by about 50% in India under the provisions of the country's new price control order. Report

> Groups are urging Vermont's governor to broaden the rules on Zogenix' ($ZGNX) powerful opioid painkiller, Zohydro. Release

> Bayer has submitted its pulmonary arterial hypertension drug riociguat for approval in Japan. Brief

Medical Device News

@FierceMedDev: Thermo soars after Life Tech deal and dials up its expectations. Story | Follow @FierceMedDev

@VarunSaxena2: Federal court postpones Edwards' block of Medtronic's CoreValve. More | Follow @VarunSaxena2

@EmilyWFierce: Cleveland startup won JDRF support for its rapid-acting insulin analog for Type 1 diabetes. News | Follow @EmilyWFierce

@MichaelGFierce: X-ray-activated nanoparticles release #cancer-killing light deeper into tissue. More from FierceDrugDelivery | Follow @MichaelGFierce

> AdvaMed casts a skeptical eye at FDA's new expedited approval idea. Story

> Boston Scientific eyes FDA with new leads. News

Biotech News

@FierceBiotech: Shooting for IPO glory, Alder cites trial success with migraine drug. More | Follow @FierceBiotech

@JohnCFierce: Amgen beats a path to the FDA, looking for an early approval of leukemia drug. Story | Follow @JohnCFierce

@DamianFierce: BMY pal Alder hit the mark in a migraine trial, good news on the eve of its IPO. News | Follow @DamianFierce

@EmilyMFierce: TB drug could be basis for class of broad-spectrum treatments. More from VaccinesNewsDaily | Follow @EmilyMFierce

> Kala reels in $22.5M to get its next-gen eye drops into PhIII. News

> Spectrum touts PhII cancer data, plans NDA. Item

> Allergan fashions a poison pill as raiders at Valeant promise to gut R&D. Story

Drug Delivery News

> Hydrocarbon double stapling of peptides a new trick in fight against viruses. Report

> Mylan launches first generic transdermal contraceptive patch. News

> X-ray-activated nanoparticles release cancer-killing light deeper into tissue. Article

> Stanford team finds that nanotubes catch a ride with immune cells to reach tumors. More

> DNA nanocages that act like viruses bypass the immune system to deliver drugs. Story

> ProNAi, with delivery tech licensed from Marina, snags $59.5M for cancer trials. Item

Diagnostics News

> MDxHealth broadens reach of prostate cancer Dx with new U.S. PPO deal. News

> Investors initially respond well to Abbott's diagnostics gains. More

> Cepheid's 2014 Q1 produced Dx sales hikes but also more losses. Report

> UW-Madison team concocts asthma blood Dx that could work before symptoms appear. Story

> KineMed, with IPO in sight, joins global diabetes biomarker research project. Article

Pharma Marketing News

> Google exec figures pharma could go viral on YouTube--if it tried. News

> Big Pharma sees danger, not safety, in FDA's new social media guidance. Story

> It's official: Gilead's Sovaldi zooms past previous records with fastest-ever drug launch. Article

> Allergan sales force key to Valeant chief's plans for post-merger growth. Report

> Doc offices that nix free samples cut way back on branded scripts: JAMA study. More

> Lilly nabs FDA approval for its blockbuster cancer hopeful ramucirumab. Item

And Finally... Major League Soccer club the Philadelphia Union has added Novo Nordisk ($NVO) to its list of corporate partners. More

 

Suggested Articles

The FDA has granted Amarin's Vascepa a possible blockbuster label expansion for CV risk reduction in patients with or without CV disease.

In a high-stakes patent lawsuit between CAR-T companies Bristol-Myers Squibb and Gilead Sciences, BMS has come up with a victory. 

It’s been a year of ups and downs for Pfizer’s Xeljanz. But the company is hoping to close on a high note, with help from a new extended-release pill.